ArticleBMJ open gastroenterology2025

Adebrelimab plus capecitabine versus capecitabine monotherapy for adjuvant treatment of high-risk resected cholangiocarcinoma (ACHIEVE): protocol for a phase II, multicentre, randomised controlled trial.

Yuan Cheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.